🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. EDP-420 / Duration of Treatment - 3 days

    ENANTA PHARMACEUTICALS INC

    Community Acquired Pneumonia

    phase 2 small molecule active

    1 trial

  2. EDP-938

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    6 trials

  3. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus Infections

    phase 2 small molecule terminated

    1 trial

  4. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus

    phase 2 small molecule completed

    1 trial

  5. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus (RSV)

    phase 2 small molecule completed

    2 trials

  6. EDP-938 Dose 1

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 2 small molecule completed

    1 trial

  7. EDP-938, EDP-938 Placebo tablets

    ENANTA PHARMACEUTICALS INC

    Respiratory syncytial virus (RSV)

    phase 2 small molecule active

    1 trial

  8. EGF816, EGF816, LEE011, LEE011

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  9. EGF816, INC280, EGF816, GEFITINIB, INC280, EGF816

    Novartis Pharmaceuticals

    cMET-dependent malignancies

    phase 2 small molecule active

    1 trial

  10. ELX-02

    Eloxx Pharmaceuticals

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  11. ELX-02

    Eloxx Pharmaceuticals

    Genetic Disease

    phase 2 small molecule terminated

    2 trials

  12. ELX-02

    Eloxx Pharmaceuticals

    Alport Syndrome

    phase 2 small molecule completed

    1 trial

  13. ENMD-2076

    CASI Pharmaceuticals

    Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  14. ENMD-2076

    CASI Pharmaceuticals

    Advanced Adult Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  15. ENMD-2076

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  16. ENTECAVIR , Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, TENOFOVIR DISOPROXIL , TENOFOVIR ALAFENAMIDE , -, VAY736

    Novartis Pharmaceuticals

    Diffuse cutaneous systemic sclerosis (dcSSc)

    phase 2 small molecule active

    1 trial

  17. EP-104GI

    EUPRAXIA PHARMACEUTICALS INC.

    Eosinophilic Esophagitis

    phase 2 small molecule active

    1 trial

  18. EP-104IAR 25 mg

    EUPRAXIA PHARMACEUTICALS INC.

    Osteoarthritis, Knee

    phase 2 small molecule completed

    1 trial

  19. EP0062, ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  20. EPI-321

    Biotech Pharmaceutical Co.,

    Facioscapulohumeral Muscular Dystrophy

    phase 2 mab active

    1 trial

  21. EPI-7386, Xtandi - 40 mg soft capsules

    Lacuna Pharma Pty Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  22. EPINEPHRINE NASAL SPRAY, Placebo Nasal Spray, EPINEPHRINE NASAL SPRAY

    Ars Pharmaceuticals Irl Limited

    Chronic Spontaneous Urticaria (CSU)

    phase 2 small molecule active

    1 trial

  23. ETOPOSIDE, YTB323, CYTARABINE, CYCLOPHOSPHAMIDE MONOHYDRATE, BENDAMUSTINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, TOCILIZUMAB

    Novartis Pharmaceuticals

    High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  24. EYU688

    Novartis Pharmaceuticals

    Dengue

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources